Beating cancer,
one test at a time

 

Oncimmune profiles the body’s immune response to detect evidence of the body’s natural response to cancer, which can be detected far earlier than cancerous cells themselves, or the cancer’s DNA.

 

Our proprietary platform

Our proprietary platform — underpinned by our comprehensive immunogenic protein library — has a role in supporting case-selection, complementing diagnostic evidence, and facilitating therapeutic decision-making; and is a keystone to the future of cancer care.

 

Our patented technology measures blood levels of autoantibodies to tumour-associated antigens, the combination of which is highly specific for target cancers, whose characteristic signal can be detected four years or more before standard clinical diagnosis.

 

Earlier Detection

Enabling the earliest detection of cancer is key to timely initiation of treatment, potentially saving lives and significantly reducing healthcare costs.

 
 
full width image

Partnering

Our tests are complementary to in vitro and in vivo diagnostic technologies, making them valuable additions to both established and new care pathways, potentially generating more information and greater confidence in determining appropriate treatment selection.

We partner with leading developers and distributors to make our technology available globally.

 

Oncimmune is changing how clinicians, researchers, and patients view, diagnose, and treat cancer. Whilst early detection is already improving cancer survival, immuneprofiling is the frontier to improving outcomes.

 

  • Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT—Lung and EarlyCDT—Liver.
  • To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT—Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland.
  • Oncimmune, headquartered in Nottingham, UK with a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China.
  • Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

Leading Early Cancer Biomarker Technology